LONDON (Alliance News) - Clinical stage biotechnology company ValiRx PLC said Thursday its clinical study report on lung cancer drug VAL401 has been signed and approved by principal investigators.
Shares in ValiRx were down 7.0% at 2.32 pence on Thursday.
VAL401 is an oral treatment of late stage non-small cell lung adenocarcinoma, and the process of submission and approval for the drug with a local ethics committee has begun.
"Commercial activity surrounding VAL401 has continued. Detailed discussions are in progress in respect to a pivotal phase III clinical trial," the company said.
ValiRx's external partners are to have significant input into the design of the clinical trial and first dosing is to commence next year.
Another of the company's treatments, VAL201, is currently in Phase I/II clinical trials for patients affected by prostate cancer. These clinical studies have shown VAL201 to have high tolerability and safety. Preliminary data inspection is complete a highlights a "dose-related impact" on patients both physiologically and chemically. ValiRx said that these results were in line with anticipated outcomes in terms of cancer reduction.
"VAL401 has demonstrated therapeutic efficacy, VAL201 is increasingly showing its therapeutic potential and our pre-clinical compounds and platform continue to progress along the value-chain and towards the clinic," said ValiRx Chief Executive Satu Vainikka.
ValiRx (VAL)